- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05163678
Evaluation of the Future of Adolescents and Young Adults Received in an Early Care System (ReFSEF)
This is a prospective clinical epidemiology study based on the naturalistic follow-up of a cohort of 1 500 young people aged 11 to 25 presenting consecutively over the course of one year at the Relais d'Ile de France.
Young people will be assessed on entry into the system (T0), at the end of the follow-up (T1) and 6 months after the end of the follow-up (T6).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Psychic suffering is very common among young people; a public health issue in France is to improve its early identification and treatment. To this end, the Fondation Santé des Etudiants de France (FSEF) has developed ambulatory systems in France called "Relais Collégiens-Lycéens-Etudiants" offering adolescents and young adults a reception, evaluation and support or a quick referral.
The FSEF Relay system allows a wide range of subjects to benefit from rapid support for a situation of mental suffering, which specialized care structures cannot do. In fact, first of all, if the school teams and the entourage are not made aware of the need to be attentive to psychological suffering, it is not detected, then when it is, most of these young people are not. not addressed out of reluctance from those around them or from the young person himself who refuse to go to psychiatric care experienced as stigmatizing; then, when young people are referred to care structures, consultation times are unsuitable (saturated structures) while these young people need a rapid response. The impact of early detection systems in adolescence has been little studied, this research proposes to initiate such an approach on a large panel of young people from a systematic evaluation, by evaluating the future in the short and medium term.
This research proposes to assess the impact of these devices. T his is a prospective clinical epidemiology study based on the naturalistic follow-up of a cohort of 1,500 young people aged 11 to 25 presenting consecutively over the course of one year at the 5 Relais d'Ile de France. Young people will be assessed on entry into the system (T0), at the end of the follow-up (T1) and 6 months after the end of the follow-up (T6). The data collected will be:
- The state of health (including mental health, somatic health and drug consumption), lifestyle and education and social adaptation through clinical assessment and self-questionnaires completed by young people:
- The clinical assessment includes the following elements: the severity of the psychological suffering (CGI, Global Clinical Impression), the psychosocial impact (SOFAS, Social and Occupational Functioning Assessment Scale) and the diagnosis of mental disorder according to the ICD 10 (International Classification) 10th Revision) when relevant.
- The self-questionnaires assess psychological suffering (K10, Kessler scale 10 items), social functioning (WSAS, Work Social Adjustment Scale) as well as satisfaction with the care provided (CSQ-8, Client Satisfaction Questionnaire 8 items, and Likert scale, at T1 and T6).
- The EDGAR grid (Interview, Approach, Group, Support, Meeting) to quantify the care offered at the Relais and their cost.
- The orientation that may be offered following this support
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Nathalie Godart, PU-PH
- Phone Number: 0145894339
- Email: nathalie.godart@fsef.net
Study Locations
-
-
-
Aire-sur-l'Adour, France, 40800
- Not yet recruiting
- Relais - Centre Adour
-
Contact:
- Catherine Viginiat
-
Neufmoutiers en Brie, France, 77000
- Recruiting
- Relais 77
-
Contact:
- Michele Simon
-
Sceaux, France, 92330
- Recruiting
- Relais 93 - Sceaux
-
Contact:
- Nadege Dumas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All adolescents, young adults in the age group 11-25 years,
- Presenting ill-being or psychological suffering, living in the health area concerned,
- Arriving alone or accompagniead at the "Realis" during the sudy period
- Agreeing to participate.
Exclusion Criteria:
- Young people outside the 11-25 age group,
- Parents and children who do not speak French or who cannot read or write.
- Young people in crisis situations requiring immediate hospitalization without consultation at the Relais.
- Refusal to participate
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
patient group
All adolescents or young adults presenting for a consultation in the FSEF "Relais" systems. They will be assessed upon entry into the device (T0), at the end of the follow-up (T1) and 6 months after the end of the follow-up (T6). |
Assessment at the start of care in the "Relais" (T0), at the end (T1) and 6 months later (T6).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Detailed description of the socio-demographic characteristics of the population hosted in the Relais
Time Frame: To the inclusion of young people
|
Socio-demographic description of the population (Sex, age,nationality, civil and family situation, education)
|
To the inclusion of young people
|
|
Detailed description of the socio-demographic characteristics of the population hosted in the Relais
Time Frame: To the inclusion of young people
|
By whom it is addressed, the reasons for addressing it, the level of mental suffering, the severity of the situation (diagnostic).
|
To the inclusion of young people
|
|
Detailed description of the socio-demographic characteristics of the population hosted in the Relais
Time Frame: To the inclusion of young people
|
The psycho-social impact of the difficulties will also be assessed, also including data on the school career and the types and intensity of care generated, the duration of the follow-up, the diagnosis made and the orientation proposed, if applicable.
|
To the inclusion of young people
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The futur of young people taken care of in the "Relais"
Time Frame: End of care (care between 6 months to 1 year) and 6 months after end of follow-up
|
Assessment of the fate at the end of the care and at 6 months, of adolescents and young adults received at least once as part of a consultation in a Relay.
The criteria will relate to the assessment at the end of treatment and then at 6 months there of, in comparison with the initial state.
These comparisons will relate to the level of psychological suffering, the psycho-social impact, and the implementation of the recommended care.
|
End of care (care between 6 months to 1 year) and 6 months after end of follow-up
|
|
Satisfaction of subjects and his parents
Time Frame: End of care (care between 6 months to 1 year) and 6 months after end of follow-up
|
Evaluate the level of satisfaction by means of a questionnaire of the subject and his parents with regard to the intervention and the orientation within the framework of the Relay schemes at the end of the care and at 6 months.
|
End of care (care between 6 months to 1 year) and 6 months after end of follow-up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nathalie Godart, PU-PH, Fondation Santé des Étudiants de France
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- FSEF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychological Distress
-
Universita di VeronaUniversity of Roma La SapienzaRecruitingDistress, Emotional | Distress, PsychologicalItaly
-
Utah State UniversityCompletedPsychological Distress | Psychological Flexibility | Psychological Well-BeingUnited States
-
Universidad de las Americas - QuitoRecruitingPsychological DistressEcuador
-
Barbel KnauperNot yet recruitingPsychological DistressCanada
-
Fondazione IRCCS Policlinico San Matteo di PaviaCompletedPsychological DistressItaly
-
Azienda Unita Sanitaria Locale di PiacenzaUniversity of Siena, ItalyCompleted
-
International Islamic University MalaysiaCompletedPsychological DistressSingapore
-
George Washington UniversityWorld Health Organization; Transcultural Psychosocial Organization Nepal; Socios... and other collaboratorsCompletedPsychological DistressNepal, Peru, Uganda
-
University of LincolnLincolnshire Partnership NHS Foundation TrustCompletedPsychological DistressUnited Kingdom
-
University of Massachusetts, BostonNational Institute of Mental Health (NIMH)Completed
Clinical Trials on monitoring naturalistic of cohort
-
Yale UniversityCompletedOpioid DependenceUnited States
-
Universitaire Ziekenhuizen KU LeuvenGeneral Hospital GroeningeUnknown
-
Wuhan YZY Biopharma Co., Ltd.CompletedMetastatic or Locally Advanced Solid TumorsChina
-
Wuhan YZY Biopharma Co., Ltd.Completed
-
Wuhan YZY Biopharma Co., Ltd.CompletedHER2-Positive Solid TumorsChina
-
Riphah International UniversityCompleted
-
Societat Catalana de Medicina Familiar i Comunitària...University of Barcelona; Fundacio d'Investigacio en Atencio Primaria Jordi...Enrolling by invitationHeart Failure | Cardiomyopathies | Arterial Hypertension | Atrial Fibrillation (AF) | Valvular Heart DiseasesSpain
-
University of Alabama at BirminghamNational Institute on Minority Health and Health Disparities (NIMHD)Not yet recruitingBMI | Diabetes (DM) | Weight Change | Blood Cholesterol | Diabetes Education | Blood Pressure MonitoringUnited States
-
Candesant Biomedical, Inc.CompletedPrimary Axillary HyperhidrosisUnited States
-
Novartis PharmaceuticalsCompletedPrimary Sjögren's SyndromeUnited States, Hungary, Germany, Switzerland, United Kingdom